EP Patent

EP0967214A1 — Intranasal formulations for treating sexual disorders

Assigned to Pfizer Ltd Great Britain · Expires 1999-12-29 · 26y expired

What this patent protects

Intranasal formulations of sildenafil mesylate for the treatment of male erectile dysfunction or female sexual disorders.

USPTO Abstract

Intranasal formulations of sildenafil mesylate for the treatment of male erectile dysfunction or female sexual disorders.

Drugs covered by this patent

Viagra (Sildenafil Citrate) · Pfizer Inc.

Patent Metadata

Patent number: EP0967214A1
Jurisdiction: EP
Classification: —
Expires: 1999-12-29
Drug substance claim: No
Drug product claim: No
Assignee: Pfizer Ltd Great Britain
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.